Taxonomic Characterization, Antiviral Activity and Induction of Three New Kenalactams in Nocardiopsis sp. CG3

DNA, Bacterial Antiviral Agents Microbiology Biochemistry Gene Article 03 medical and health sciences Context (archaeology) Methionine FOS: Chemical sciences RNA, Ribosomal, 16S Biochemistry, Genetics and Molecular Biology Health Sciences RNA Sequencing Data Analysis Molecular Biology Biology Phylogeny Soil Microbiology Pharmacology 0303 health sciences Chemical Glycobiology and Therapeutic Applications Organic Chemistry Life Sciences Strain (injury) Paleontology Nocardiopsis Natural Products as Sources of New Drugs Sequence Analysis, DNA Functional Genomics Amino acid 3. Good health Actinobacteria Chemistry FOS: Biological sciences Physical Sciences Medicine Anatomy 16S ribosomal RNA
DOI: 10.1007/s00284-022-02954-x Publication Date: 2022-08-10T06:02:48Z
ABSTRACT
AbstractExploration of secondary metabolites secreted by new Actinobacteria taxa isolated from unexplored areas, can increase the possibility to obtain new compounds which can be developed into new drugs for the treatment of serious diseases such as hepatitis C. In this context, one actinobacterial strain, CG3, has been selected based on the results of polyphasic characterization, which indicate that it represents a new putative species within the genus Nocardiopsis. Two fractions (F2 and F3), prepared from the culture of strain CG3 in soybean medium, exhibited a pronounced antiviral activity against the HCV strain Luc-Jc1. LC–HRESIMS analysis showed different bioactive compounds in both active fractions (F2 and F3), including five polyenic macrolactams (kenalactams A-E), three isoflavone metabolites, along with mitomycin C and one p-phenyl derivative. Furthermore, feeding with 1% of methionine, lysine or alanine as a unique nitrogen source, induced the production of three novel kenalactam derivatives.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....